Cystic fibrosis (CF)
Top performance based onrobust DELFIA®
chemistryThe Neonatal IRT assay provides highanalytical
sensitivity with the limit ofblank of 0.43 ng/mL for DELFIA and0.53
ng/mL for AutoDELFIA platforms.Intra-assay imprecision for the
clinicallyrelevant area is close to 9% for bothassays. All
calibrators and controls arelot-specifi c to ensure that every lot
is of thesame level.
Fully automated AutoDELFIA®system leads the way in
termsof results qualityThe automatic system allows for the
bestassay performance in terms of precision,and brings robustness,
reliability andcost-effectiveness to your CF
Early diagnosis for betterquality of lifeCystic fi
brosis is a common geneticdisorder affecting 1 in 2,500
Caucasians.The diagnosis is often based on thesymptoms which may
cause considerabledelays in the disease intervention, andevidence
indicates that early attention maybe important in determining the
clinicaloutcome. The amount of the pancreaticenzyme, immunoreactive
trypsin (IRT) hasbeen shown to be increased in blood of CFpatients
especially during the fi rst weeksafter birth.
PerkinElmer's Neonatal IRT assay allowsthe quantitative
determination of IRTfrom dried blood spot specimens, and isintended
as an aid in screening for CF.